<DOC>
	<DOC>NCT01507922</DOC>
	<brief_summary>It is a randomized double-blind parallel phase IV study to compare Fenoverine and Trimebutine maleate in the efficacy and safety. Study Hypothesis: Fenoverine is non-inferior to Trimebutine maleate in its efficacy and safety.</brief_summary>
	<brief_title>Comparative Efficacy and Safety of Fenoverine</brief_title>
	<detailed_description>For subjects with IBS, Fenoverine and Trimebutine will be administered orally for 8 weeks; Fenoverine 100mg capsule three times a day and Trimebutine 150mg tablet three times a day. Because one is capsule and the other is tablet, double dummy design will be used. Efficacy is evaluated at the end of 8 weeks and safety will be followed for 4 more weeks after the end of the scheduled medication.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Fenoverine</mesh_term>
	<mesh_term>Trimebutine</mesh_term>
	<criteria>18 years of age or older and 60 years of age or younger Diagnosed as irritable bowel syndrome using Rome III Criteria Female subjects of childbearing potential are confirmed to have a negative urine betahCG test within 7 days prior to administration of initial dose of investigational products. Female subjects of childbearing potential must agree to use contraceptive measures during study period. Known allergy or hypersensitivity to investigational products or components of the formulation Past or current diagnosis of chronic liver disease (e.g., liver cirrhosis, acute hepatitis, alcoholic hepatitis, chronic alcohol abuse and HCC) Past or current diagnosis of Myopathy Subject with serious renal disease Known medical condition assessed by investigators as inappropriate for the study Continuous use of NSAIDS, analgesics, steroids, or other immunosuppressants. Continuous use of HMGCoA reductase inhibitors or fibrates to lower blood lipid level Pregnant, lactating, or planning to be pregnant women Evidence of abuse of drugs or alcohol within 6 months prior to screening Participation in other clinical trials within 3 months prior to enrollment or elapse of less than 5 half lives of previous investigational product after last dose of it. Unable to submit informed consent or comply with the requirements of the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Fenoverine</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Abdominal pain</keyword>
	<keyword>BSS</keyword>
</DOC>